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958 Song et alheterogeneous.2 Patients whose melanoma is diag-
nosed in stage I have a much favorable prognosis,
with a higher than 90% 5-year survival rate whereas
the 5-year survival rate for patients with stage IV
(distant) disease is around 15%.3 There has been a
discrepancy between melanoma incidence and mor-
tality over the past 2 decades; melanoma incidenceCAPSULE SUMMARY
d Previous studies have found an increased
risk for invasive cutaneous melanoma
among persons with a personal history
of keratinocyte carcinoma (KC).
d We found that individuals with invasive
cutaneous melanoma who had a history
of KC had better survival than those
without a history of KC.
d Information regarding a patient’s
personal history of KC is relevant for
melanoma prognosis.has dramatically risen, but
melanoma mortality has
recently stabilized.4,5
Keratinocyte carcinoma
(KC), including cutaneous
basal cell carcinoma (BCC)
and squamous cell carcinoma
(SCC), are the most
commonly diagnosed malig-
nancies in the United States,
with 3.5 million cases each
year.6 It has been suggested
that KC and other cancers
may share common carcino-
genic exposures or molecular
mechanisms in their etiology,
such asDNA repair deficiency
and immune suppression,
implying that ahistoryofKCmay indicatean increased
risk for subsequent cancer development. We previ-
ously reported an increased risk for cancer associated
with history of KC, including melanoma in men and
breast cancer, lung cancer, andmelanoma inwomen.7
In addition, Wu et al recently reported that a personal
history of KC was associated with increased risk for
melanoma (hazard ratio [HR], 2.22; 95% confidence
interval [CI], 1.73-2.85),8 which is consistent with
previous reports from registry-based, case-control,
and prospective cohort studies.9-12
Although the association of a personal history of
KC with melanoma risk has been consistently
reported, its association with melanoma mortality
remains undetermined. A study 2 decades ago
reported that increased mortality due to overall
cancer and melanoma after the diagnosis of KC
may be due to shared exposures or susceptibilities.13
However, this association was not further replicated
in later years.14 Does a history of KC increase the risk
for melanoma death, and do patients with melanoma
with a history of KC have poorer prognoses? To
answer these questions, we conducted a prospective
cohort study using data from the Health
Professionals Follow-up Study (HPFS).
METHODS
Study population
The HPFS was started in 1986 and enrolled 51,529
American male health care professionals age 40 to75 years. Participants receive a biennial survey
regarding their personal health information and
lifestyle. Response rates are higher than 90%. Our
study period includes data collected from the cohort
in surveys from 1986 to 2012. Only white patients
(both Hispanic and non-Hispanic whites) were
included in our analysis, given the different risksfor development of mela-
noma among different
races.15 Our study was
approved by the Human
Research Committee of the
Harvard T.H. Chan School of
Public Health (Boston, MA).
Assessment of exposure
In the HPFS, participants
were asked about having
received a diagnosis of BCC
and SCC. Medical and path-
ological reports were ob-
tained from participants
who reported SCC to confirm
the diagnosis. Medical re-
cords were not obtained forBCC cases because of a large number of cases in our
cohort and because previous validation studies
reported a more than 90% accuracy of self-reported
BCC among subsets of cohort participants.16
Assessment of melanoma and death
Similar to assessment of exposure as already
detailed, participants in both cohorts self-reported
a diagnosis of melanoma. Afterward, permission
was sought to access their medical records so that
pathologic reports could be reviewed. We focused
only on the mortality of confirmed invasive cases,
and excluded those participants with lentigo
maligna melanoma and melanoma in situ from
this analysis because of their favorable prognosis.
Self-reported cases that could not be confirmed
were excluded. Information collected aside
from melanoma diagnosis included major
histopathologic factors, such as Breslow depth
and Clark level. All information was updated up
to 2012.
Death events were reviewed in 1 of 3 ways.
Deaths were reported by next of kin or by the US
Postal Service. Additionally, a searchwasmade in the
National Death Index for participants who did not
respond to their surveys. Death certificates andwhen
necessary, medical records, were used to determine
the date of death. More than 98% of deaths in these 2
cohorts were confirmed by 1 of these methods.17
Furthermore, cause of death was determined by
Abbreviations used:
BCC: basal cell carcinoma
CI: confidence interval
CM: cutaneous melanoma
HPFS: Health Professionals Follow-up Study
HR: hazard ratio
KC: keratinocyte carcinoma
OR: odds ratio
SCC: squamous cell carcinoma
UV: ultraviolet
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certificates. This was supplemented with family or
health care provider interviews, as well as with
medical records. The primary cancer was recorded
as cause of death in cases of metastatic disease
causing death.Assessment of covariates
Covariate information was collected by self-
reported questions on the biennial surveys. This
included information on smoking, alcohol intake,
body mass index, and physical activity. Questions
about certain factors were asked at certain time
points in the cohort. These included the following
factors: number of blistering sunburns and tendency
to burn as a child or adolescent, natural hair color,
and family history of melanoma in first-degree
relatives. Additionally, ultraviolet (UV) flux was
calculated for each participant on the basis of his
state of residence and by using a previously
described method.18Statistical analysis
We calculated person-years of follow-up from
baseline to death or end of follow-up period,
whichever came first. The year 1986 was set as the
study baseline, and association of a history of KC
with subsequent diagnosis of invasive cutaneous
melanoma (CM) and melanoma death were exam-
ined until 2012 for the cohort. Melanoma deaths
were considered the major end point, whereas
deaths from other causes were censored. By using
a Cox proportional hazards model stratified by age
and follow-up cycles, we calculated HRs for mela-
noma death, comparing participants with and
without a history of KC. The analyses were adjusted
for the predetermined covariates (body mass index,
smoking, alcohol intake, physical activity, childhood
reaction to sun, number of sunburns, family history
for melanoma, hair color, UV flux, and frequency of
physical examination). Missing data for any covariate
required creation of an indicator. In a secondary
analysis, we looked at history of KC and its effect onincident cases of lethal melanoma and nonlethal
melanoma. In this analysis, follow-up time was
determined by the basis of date of melanoma
diagnosis, death from any cause, or end of follow-
up time, whichever came first. Similarly, we used a
Cox proportional hazards model with adjustment for
the same covariates.
Moreover, we analyzed the rate of death from
melanoma among invasive melanoma cases to
examine whether a history of KC is associated with
a worse prognosis. In this analysis, we included
participants from time of diagnosis of invasive
melanoma and followed them until either the pre-
determined end time or death from any cause,
whichever came first. Any death from all causes
other than melanoma death was censored. As
already described, HRs were calculated by using a
Cox proportional hazards model with time inmonths
since diagnosis as the time variable, adjusting for the
same covariates. All analyses were carried out using
SAS software (version 9.3, SAS Institute Inc, Cary,
NC). All P values were 2 tailed with the significance
level set at P less than .05.
RESULTS
A total of 579 of participants with invasive CM had
no personal history of KC in the cohort, versus 329
who did carry a prior diagnosis of KC over 0.7 million
years of follow-up. Baseline characteristics for the 2
groups are mostly similar (as shown in Table I),
except that the mean age at diagnosis for participants
with invasive CM with a history of KC was older than
that of participants without a history of KC: 72.9 years
versus 66.5 years.
We examined the risk for development of either a
lethal or nonlethal melanoma depending on history
of KC. The age-adjusted HR for development of a
lethal melanoma for those with a history of KC was
1.63 (95% CI, 1.01-2.61) when compared with those
who had no such history. In multivariate analysis,
this HR was 1.97 (95% CI, 1.21-3.20). For the risk of
nonlethal melanoma, the HRs for age-adjusted and
multivariate-adjusted modeling were 1.70 (95% CI,
1.44-2.01) and 1.61 (95% CI, 1.36-1.90) (Table II).
When the HR of melanoma mortality was evalu-
ated on the basis of a personal history of KC, the age-
adjusted HR was 1.26 (95% CI, 0.79-2.00) in the
HPFS.When covariates other than agewere included
in the model, the multivariate-adjusted HR was 1.53
(95% CI, 0.95-2.46) (Table III). In addition, no
significant association was found between a history
of KC and melanoma thickness or invasiveness. We
calculated the odds ratios (ORs) (95% CIs) for the
association between personal history of KC and
Breslow thickness of melanoma of 0.8 mm or
Table II. HRs (95% CIs) for the association between personal history of KC and risk for incident lethal melanoma
and nonlethal melanoma in the Health Professionals Follow-up Study (1986-2012)
Lethal vs nonlethal melanoma
Personal history of KC
No Yes
Lethal melanoma
Cases per 1000 person-years 0.1 (74/611067) 0.27 (28/103285)
Age-adjusted HR (95% CI) 1.00 1.63 (1.01-2.61)
Multivariate-adjusted HR (95% CI)* 1.00 1.97 (1.21-3.20)
Nonlethal melanoma
Cases per 1000 person-years 0.96 (586/611067) 2.04 (211/103285)
Age-adjusted HR (95% CI) 1.00 1.70 (1.44-2.01)
Multivariate-adjusted HR (95% CI)* 1.00 1.61 (1.36-1.90)
CI, Confidence interval; HR, hazard ratio; KC, keratinocyte melanoma.
*Multivariate-adjusted analyses were performed with adjustment for age, smoking (never-smokers, past smokers, or current smokers),
physical activity (in quintiles, metabolic equivalent h/wk), body mass index (\25, 25-29.9, or $30 kg/m2), alcohol intake (0, 0-4.9, 5-9.9, or
$10 g/d), childhood reaction to sun (tan without burn, burn, or painful burn/blisters), childhood tanning ability (practically none, little tan,
average tan, or deep tan), number of sunburns (0, 1-2, 3-5, or$6), hair color (red, blonde, light brown, or dark brown/black), family history of
melanoma (yes or no), cumulative ultraviolet flux (in quintiles), and physical examination frequency. An indicator variable was created for the
missing value of each covariate.
Table I. Age-standardized baseline characteristics of cases with invasive melanoma by personal history of KC in
the Health Professionals Follow-up Study (1986-2012)
Characteristic
Personal history of KC
No Yes
No. of participants 579 329
Age at diagnosis, y, mean (SD) 66.5 (10.8) 72.9 (8.5)
Body mass index, kg/m2, mean (SD) 25.6 (3.5) 25.8 (3.0)
Current smoking, % 2.9 4.6
Family history of melanoma, % 5.8 6.5
Red or blonde hair, % 18.0 21.8
Childhood/adolescent tendency to sunburn or
blistering response, %
81.2 83.1
$6 sunburns, % per United States Cancer Statistics:
1999-2014 Incidence and Mortality Web-based Report
41.8 44.9
UV flux, 3104 RB units, mean (SD) 134.1 (29.0) 138.0 (28.7)
Breslow thickness, mm, mean (SD) 1.0 (1.1) 1.0 (1.5)
\1 mm, % 74.6 73.9
1-2 mm, % 17.3 19.3
[2 mm, % 9.9 8.5
Clark level IV or V, % 23.3 29.8
Body site (%)
Head and neck 36.1 36.3
Trunk 40.6 41.5
Limbs 23.3 22.2
Physical examination frequency 67.1 (29.9) 76.5 (22.6)
All values shown were for the information at melanoma diagnosis or the questionnaire cycle closest to the melanoma diagnosis year except
where otherwise noted. All variables other than age at diagnosis were adjusted for age at diagnosis.
KC, Keratinocyte melanoma; RB, Robertson-Berger; SD, standard deviation; UV, ultraviolet.
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1.83). We calculated the ORs (95% CIs) for the
association between personal history of KC and
Clark levels IV and V melanoma; the multivariate
OR was 1.69 (95% CI, 0.91-3.15).Furthermore, in the melanoma caseeonly anal-
ysis, we found that a personal history of KC
conferred an HR of 0.59 (95% CI, 0.37-0.94) in the
age-adjusted model. Multivariate modeling revealed
an HR of 0.60 (95% CI, 0.37-0.99), and in the more
Table IV. HRs (95% CIs) for the association between
personal history of KC and risk for death from
melanoma death in the Health Professionals Follow-
up Study (1986-2012): among melanoma cases only
Characteristic
Personal history of KC
No Yes
Deaths per 1000
person-years
16.7 (77/4603) 8.9 (28/3136)
Age-adjusted HR (95%
CI)
1.00 0.59 (0.37-0.94)
Multivariate-adjusted
HR (95% CI)*
1.00 0.60 (0.37-0.99)
Multivariate-adjusted
HR (95% CI)y
1.00 0.60 (0.35-0.94)
Patients with melanoma entered follow-up only after their
melanoma was diagnosed.
CI, Confidence interval; HR, hazard ratio; KC, keratinocyte
melanoma.
*Multivariate-adjusted analyses were performed with adjustment
for age, smoking (never-smokers, past smokers, or current
smokers), physical activity (in quintiles, metabolic equivalent
hours/wk), body mass index (\25, 25-29.9, or $30 kg/m2),
alcohol intake (0, 0-4.9, 5-9.9, or $10 g/d), childhood reaction to
sun (tan without burn, burn, or painful burn/blisters), childhood
tanning ability (practically none, little tan, average tan, or deep
tan, for Nurses’ Health Study only), number of sunburns (0, 1-2, 3-
5, or $6), hair color (red, blonde, light brown, or dark brown/
black), family history of melanoma (yes or no), cumulative
ultraviolet flux (in quintiles), and physical examination frequency.
An indicator variable was created for the missing value of each
covariate.
y
Table III. HRs (95% CIs) for the association
between personal history of KC and risk for death
from melanoma death in the Health Professionals
Follow-up Study
Characteristic
Personal history of KC
No Yes
Deaths per 1000
person-years
0.13 (77/612246) 0.27 (28/103592)
Age-adjusted HR
(95% CI)
1.00 1.26 (0.79-2.00)
Multivariate-adjusted
HR (95% CI)*
1.00 1.53 (0.95-2.46)
CI, Confidence interval; HR, hazard ratio; KC, keratinocyte
melanoma.
*Multivariate-adjusted analyses were performed with adjustment
for age, smoking (never- smokers, past smokers, or current
smokers), physical activity (in quintiles, metabolic equivalent
hours/wk), body mass index (\25, 25-29.9, or $30 kg/m2),
alcohol intake (0, 0-4.9, 5-9.9, or $10 g/d), childhood reaction to
sun (tan without burn, burn, or painful burn/blisters), childhood
tanning ability (practically none, little tan, average tan, or deep
tan), number of sunburns (0, 1-2, 3-5, or $6), hair color (red,
blonde, light brown, or dark brown/black), family history of
melanoma (yes or no), cumulative ultraviolet flux (in quintiles),
and physical examination frequency. An indicator variable was
created for the missing value of each covariate.
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controlled for Breslow thickness and Clark level,
the HR was 0.60 (95% CI, 0.35-0.94) (Table IV).Additionally adjusting for Breslow thickness (\1, 1-2, or[2 mm)
and Clark level.DISCUSSION
It has been reported that a personal history of KC
is associated with an increased risk for invasive
melanoma. In this prospective cohort study, we
found no significantly increased mortality from
melanoma among patients with a history of KC.
Interestingly, in the melanoma caseeonly analysis,
melanoma cases with such a history had significantly
better survival than cases without a history of KC,
suggesting a protective effect of a history of KC on
melanoma death.
This could be explained logically by the idea that
once a patient has a KC, they are more likely to
undergo serial skin examinations with a dermatolo-
gist,19 making the diagnosis of CM not only more
likely but alsomore likely to bemade earlier. Patients
with a history of KC visit their dermatologists more
often, thus having a better chance of having CMs
diagnosed before the tumors start to metastasize.20
This, combined with the previously described data
showing an increase in melanoma diagnosis after a
history of KC, suggests a detection bias leading to
higher CM diagnosis rates. However, we did notobserve that patients with a history of KC had thinner
or less invasive melanomas.
It has been proposed that a history of KC is a
marker for previous UV exposure,21 which would
explain both the increased incidence and diagnosis
of lethal and nonlethal melanoma.22 However, a
population-based study of survival after a melanoma
diagnosis suggests that some factors associated with
high levels of sun exposure, such as solar elastosis
and, to a lesser extent, sunburns and intermittent sun
exposure, are inversely associated with death from
melanoma.23 Our data were consistent with this
finding. Sun exposure is necessary for synthesis of
25-hydroxy vitamin D3 in the skin, which is then
converted to 1,25-dihydroxyvitamin D, which has
antiproliferative and proapoptotic properties. It
would be plausible to speculate that the inverse
relationship between sun exposure and survival of
melanoma could be mediated by vitamin D.
Additionally, melanomas that develop in patients
with prior KC likely occur because of similar
pathways involving UV exposure. However, mela-
nomas that occur in patients without a history of KC
J AM ACAD DERMATOL
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due to nonmodifiable host factors, such as genetic
predisposition and nevus count.24-26 The latter group
may have more aggressive melanomas leading to
death in a shorter period of follow-up. In essence, a
history of KC does increase the risk of CM and death
from it. However, if people develop a CM without a
history of KC, they are at higher risk for death, given
the possibility of a more aggressive tumor.
Our study has both limitations and strengths. One
limitation is that because the HPFS population
consists solely of male health professionals, who
may have sun exposure-related or other behaviors
different from those of the general population, the
results of this study may not be applicable to the
whole population. For example, a participant in the
HPFS study is less likely to be a current smoker
compared with the general population27 but more
likely to be a moderate or heavy drinker.28,29 In
addition, HPFS participants have higher levels of
health awareness and are more likely to undergo
screening and early detection. Furthermore, we have
documented previously that the incidence of mela-
noma is higher in our cohort30 than in the general
population,31 as high socioeconomic status and
intermittent sun exposure patterns have been asso-
ciated with an increased risk for melanoma.32 For
KC, the HPFS has an incidence similar to that in the
general population.33-35
Another limitation is that patients were studied
from 1986 to 2012, and advances in therapy for
metastatic melanoma have improved dramatically in
the past few years. As such, it is reasonable to
conjecture that if a study were to begin now, the
rate of death due to melanoma might be lower, or at
least we might see a longer time to death from
melanoma after the date of diagnosis. However, one
could also posit that with longer survival from
advanced therapies come higher costs, indicating
that prevention and early detection are still of the
utmost importance for both mortality and health care
spending. In addition, we did not have complete
information on subtype of melanoma, which is an
important factor for melanoma prognosis.
Furthermore, recall bias regarding factors such as
childhood reaction to sun, childhood tanning ability,
and times of sunburns may exist during data collec-
tion. As for strengths, participants in the HPFS are all
health care professionals. As such, their own likeli-
hood of following up with physicians after an event
such as KC is higher. Our calculations likely repre-
sent true estimates in ideal circumstances, which is
helpful when quoting risks for patients.
In summary, we found no significantly increased
mortality among people with a personal history ofKC. However, among patients with invasive mela-
noma, those with a history of KC were found to have
better survival than patients without a history of KC.
Further studies are warranted to investigate the
mechanism underlying this inverse association.
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